Jennifer Hüllein

TOPAS converts phosphoproteomic data into patient-specific reports for molecular tumor boards, focusing on clinically relevant signaling and therapeutic targets.

This study uses pan-cancer phosphoproteomics to identify therapeutic targets and improve precision oncology by analyzing 1,998 tumor samples and developing new scores for kinase activity and immune response.

The paper introduces Knowledge Connector, a decision support system that integrates multiomics data with clinical information to aid in precision oncology decision-making.

The paper uses drug perturbations and RNA sequencing to map pathway connectivity in CLL, showing how genetic aberrations modulate drug responses and pathway interactions.

aRgus provides a webtool for visualizing and analyzing non-synonymous variants with pathogenicity scoring to assess genetic vulnerability.

This study identifies subgroup-specific gene expression profiles and mixed epistasis in chronic lymphocytic leukemia using RNA-sequencing and genomic data.

This study identifies MDM4 as a critical target of 1q gain in TP53wt Burkitt lymphoma, showing its role in evading cell cycle arrest and highlighting its therapeutic potential.